BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab plus/ Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E Mutant Metastatic …

Harpreet Wasan,Tobias Arkenau,Mike Braun,Leslie Samuel,Janet Graham,Scott Kopetz,Axel Grothey,Eric Van Cutsem,Rona Yaeger,Takayuki Yoshino,Jayesh Desai,Fortunato Ciardello,Ashwin Gollerkeri,Kati Maharry,Victor Sandor,Janna Christy-Bittel,Lisa Anderson,Josep Tabernero

BRITISH JOURNAL OF CANCER（2019）

引用 0|浏览5

暂无评分

摘要

logo search. National-Cancer-Research-Institute (NCRI) Cancer Conference, Date: 2019/11/03 - 2019/11/05, Location: Glasgow, SCOTLAND. Publication date: 2019-10. Volume: 121 Pages: 24 - 24. ISSN: 0007-0920, 1532-1827. Publisher: Springer Nature [academic journals on nature.com]. BRITISH JOURNAL OF CANCER. BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab plus /- Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer Patients. Author: Wasan, Harpreet. Arkenau, Tobias ; Braun, Mike ; Samuel, Leslie ; Graham, Janet ; Kopetz, Scott ; Grothey, Axel ; Van Cutsem, Eric ; Yaeger, Rona ; Yoshino, Takayuki ; Desai, Jayesh ; Ciardello, Fortunato ; Gollerkeri, Ashwin ; Maharry, Kati ; Sandor, Victor ; Christy-Bittel, Janna ; Anderson, Lisa ; Tabernero, Josep. Keywords …

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要